Rayner Surgical Group

Developer and manufacturer of intra-ocular lenses

rayner.com
Date Invested
January 2017
Status
Realised

At a glance

>80
countries exported to
>650,000
eyes with improved vision per year
11
new products launched in 5 years

Rayner is a leading developer and manufacturer of ophthalmic implants and pharmaceuticals. Led by CEO Tim Clover, it specialises in providing intra-ocular lenses and related products used in cataract and refractive surgery that improve the eyesight of patients worldwide.

Rayner is a global business. Its products are available in over 80 countries both through its own subsidiaries as well as a wide network of distributors.

Our partnership

Phoenix worked with the Rayner team to accelerate the development of a number of new products, to strengthen its international reach and to complete a number of strategic acquisitions. We also worked with the team to transition the business into its new state-of-the-art facility in Worthing.

During the period of Phoenix’s investment, revenues nearly doubled, EBITDA nearly trebled and employee numbers increased by more than 75%. Rayner was sold to CVC Capital Partners in July 2021, generating a 4.3x return on investment.

"Our partnership with Phoenix helped to accelerate our growth plans by providing us with the support and resources to develop and launch new products, contributing to improvements in visual outcomes for surgeons and patients worldwide."

Tim Clover, CEO of Rayner Surgical Group